Temporary scheduling is an expedited procedure under 21 U.S.C. 811(h) that lets the DEA place a substance into Schedule I without the full notice-and-comment rulemaking a permanent scheduling action requires. The agency publishes a Notice of Intent, waits a minimum of thirty days, then issues an order that takes effect on the day it publishes in the Federal Register. The listing runs for two years, can be extended by one, and the statute bars judicial review of the order.
That last point is the part most people miss, and the thirty-day wait is the part most people misread. This post walks through the mechanism in order, using the July 2026 kratom-derivative filings as the working example.
Quick Reference: The 811(h) Mechanism
| Step | What happens |
| Notice of Intent filed | DEA states publicly that it intends to schedule. |
| Publication in the Federal Register | The clock starts. Published 2026-07-06. |
| 30-day minimum waiting period | The order may not issue during this window. Minimum, not maximum. |
| Order issued and published | Effective on the date of publication. On or after 2026-08-05 here. |
| Duration | Two years, extendable by one additional year. |
| Judicial review | Barred by the temporary scheduling statute. |
What Temporary Scheduling Is Actually For
Permanent scheduling is slow by design. It requires a formal evaluation, a scientific and medical review from the Department of Health and Human Services, notice-and-comment rulemaking, and an administrative record capable of surviving a challenge. That process routinely takes years.
Congress added the temporary scheduling authority because the slow process was being outrun. A compound would appear, gain distribution, and by the time the permanent machinery had ground through its steps, the market had already shifted to a structurally adjacent molecule. The expedited route was built to close that gap: it lets DEA act on a finding that scheduling is necessary to avoid an imminent hazard to the public safety, and it lets the agency act on a much thinner record than permanent scheduling demands.
The trade-off Congress made is explicit. Speed in, procedural protections out. Temporary scheduling skips the health-agency medical evaluation as a precondition, skips notice-and-comment, and — as covered below — skips judicial review entirely. It is one of the more procedurally lopsided tools in federal administrative law, and it exists precisely because the alternative was judged worse.
Step One: The Notice of Intent
The process opens with a Notice of Intent published in the Federal Register. The Notice is not the ban. It is a formal statement that the agency intends to issue a scheduling order, identifying the substances by chemical name and specifying the scope of the proposed listing.
DEA filed two separate Notices of Intent, which published on 2026-07-06 as FR Doc 2026-13580 and FR Doc 2026-13581. The split matters: the first covers 7-hydroxymitragynine above a specified threshold, and the second covers mitragynine pseudoindoxyl, MGM-15 and MGM-16 with no threshold at all. Two documents, two different standards, one shared timeline. We have broken down the threshold arithmetic separately in our explainer on the 0.050% and 1.00 mg thresholds, and the no-threshold listing in the piece on MGM-15 and MGM-16.
The Notice also serves an evidentiary function that sellers frequently underestimate. Once it publishes, nobody in the trade can credibly claim they did not know what was coming. Publication is constructive notice to the entire industry.
Why the 30 Days Is a Constraint on DEA, Not a Runway for Sellers
This is the single most misread provision in the statute, and the misreading has cost people money.
The statute says the order may not issue for at least thirty days after the Notice of Intent publishes. Read the direction of that sentence carefully. It is a restriction placed on the agency. It tells DEA when it is permitted to act. It is not a permission slip issued to anyone else, and it grants no rights to distributors, retailers, or consumers.
The practical consequence is that the thirty days expires before the order issues. It is not a wind-down window that starts on the effective date and runs afterwards. It is a delay that runs beforehand and is already over by the time anything changes. When the order publishes, the change is immediate and total.
There is a second, related confusion worth naming. Scheduling orders often do contain thirty-day allowances — but those allowances run to existing DEA registrants and cover paperwork only: labeling and packaging updates, initial inventory, recordkeeping. If someone tells you "DEA always gives thirty days to clear inventory," they have taken a registrant paperwork provision and generalised it into something it never said. A retailer who holds no DEA registration receives nothing from it.
Note also that thirty days is a floor, not a ceiling. DEA's stated intent is to issue the order as soon as possible after the thirty days expire, which is why 2026-08-05 is the earliest realistic date rather than a guaranteed one. Planning around a later date is a bet with no upside — the compliant posture is to be ready by the earliest date and treat any additional time as luck. We cover the operational side of that in what actually changes on August 5.
"Not Subject to Judicial Review": What That Means
The statutory text is short: an order issued under the temporary scheduling provision is not subject to judicial review.
Ordinarily, a party harmed by an agency action can go to federal court and argue the agency got it wrong, exceeded its authority, or failed to consider the evidence. That route is closed here. There is no petition for review of the temporary order, no federal restraining order to pause the effective date while a challenge proceeds, no stay pending appeal. The order takes effect and stays in effect for its full term regardless of what anyone files.
DEA also takes the position that a temporary order is not a "rule" for these purposes, and on that basis disclaims the federal notice-and-comment requirements and the small-business impact analysis that normally attach to rulemaking. The downstream effect is worth stating plainly: no analysis of small-business impact or inventory loss is ever performed. The economic cost to a small retailer holding affected stock is not weighed, not estimated, and not entered into the record anywhere.
None of this is unusual for a temporary scheduling action. It is the design.
Two Years, Plus One
A temporary order remains in effect for two years from its effective date. DEA may extend it by up to one additional year if permanent scheduling proceedings are underway. The maximum life of a temporary listing is therefore three years.
What happens at the end is not predetermined. The usual path is that permanent scheduling proceedings conclude during the temporary period and the substance moves to a permanent listing. But temporary scheduling does not guarantee that outcome. Temporary status is a holding position, not a verdict.
For anyone in the trade, the practical read is that a two-to-three-year horizon is long enough that "waiting it out" is not a business strategy. A product category that disappears from lawful retail for two years does not return to the same market it left.
How This Applies to the July 2026 Filings
Applied to the current action, the mechanism produces this: the Notices published 2026-07-06, the thirty-day minimum expires on 2026-08-05, and the orders may issue on or after that date, taking effect the day they publish. There will be no comment period that changes the outcome, no court that pauses it, and no transition period for anyone holding affected stock. For the broader question of what falls inside the scope, see our overview of the 7-OH action.
Cat's Claw (Uncaria tomentosa) is a different plant from kratom (Mitragyna speciosa) and is not named anywhere in either Notice. That is a factual observation about the scope of the filings, and it is worth being precise about what it does and does not establish. It means the botanical itself is not scheduled. It does not, on its own, tell you what is inside any particular finished product sold under any particular label. The side-by-side is in Cat's Claw vs kratom vs 7-OH.
Where We Stand On Testing
Botanical Blends is a distributor and retailer. We do not manufacture, formulate, or blend anything — we carry other companies' brands, and the testing we can point to is the testing those brands' suppliers commission. Any description of what a given product contains comes from the brand's own product listing, not from us. Being straight about the limits of that documentation is the whole of our position.
The supplier certificates we hold report non-detect for 7-hydroxymitragynine and mitragynine. That is the substantiated basis for describing what we carry as kratom-free, no mitragynine, no 7-OH, and it is the claim we stand behind and no more. Those documents are published on our certificate of analysis page.
Those same panels do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B. A panel cannot clear a compound it never looked for, so we do not describe the products we carry as free of those four, we do not claim they are free of "all scheduled compounds," and you should treat any seller who does as having gone beyond their own paperwork. If you want the fuller version of that argument, we wrote it up in how to read a certificate of analysis.
Frequently Asked Questions
Does the thirty-day waiting period mean I can keep selling for thirty more days?
No. The thirty days is a restriction on when DEA may issue its order, and it expires before the order issues. It confers nothing on sellers and creates no sell-through window. Once the order publishes, the change is immediate.
Can the temporary scheduling order be challenged in court?
Not the order itself. The temporary scheduling statute states that an order issued under it is not subject to judicial review. Related state-level actions and enforcement decisions can be litigated on their own terms, but the federal temporary order is insulated.
Is temporary scheduling the same as a permanent ban?
No. A temporary order lasts two years and may be extended by one. Permanent scheduling requires a separate process, including health-agency review and notice-and-comment rulemaking. Temporary status usually precedes a permanent decision but does not determine it.
Why did DEA file two separate notices instead of one?
Because the two sets of substances get different treatment. FR Doc 2026-13580 applies a threshold to 7-OH; FR Doc 2026-13581 applies no threshold to mitragynine pseudoindoxyl, MGM-15 and MGM-16, capturing any detectable amount. Combining them into one document would have blurred a distinction that carries real consequences.
Where can I read the primary text myself?
Search the Federal Register for FR Doc 2026-13580 and FR Doc 2026-13581, both published 2026-07-06. We also keep a plain-language walkthrough of the action at what happens to 7-OH brands. Nothing on this site is legal advice; if you hold inventory, talk to a lawyer.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.